O33.F Glycorex Transplantation AB (publ)
- Market cap
- EUR 11.9M
- P/E
- -
- P/B
- 4.83x
- ROE
- -58.3%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is O33.F undervalued?
Graham numberThe Graham number of Glycorex Transplantation AB (publ) cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Glycorex Transplantation AB (publ) fundamental analysis
No fundamental analysis for Glycorex Transplantation AB (publ) yet.
Glycorex Transplantation AB (publ) stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Glycorex Transplantation AB (publ)
Glycorex Transplantation AB (publ), a medical technology company, research, develops, manufactures, markets, and sells products in the field of organ transplantation or related areas. It develops an antigen-specific immunoadsorption to reduce blood group antibodies and autoantibodies in the blood. The company's principal product is Glycosorb-ABO, which enables blood group incompatible kidney transplantation and is also used to enable heart, liver, lung, and stem cell transpl…
Full company profileGlycorex Transplantation AB (publ) financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Glycorex Transplantation AB (publ) annual financial statements (SEK; K = thousand, M = million, B = billion, T = trillion)
| Item | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|
| Income Statement | ||||||
| Revenue | 28.2M | 36.1M | 30.0M | 35.2M | 38.8M | 30.8M |
| Gross Profit | 24.9M | 31.5M | 26.9M | 28.2M | 32.2M | 25.2M |
| Operating Income | -11.8M | -8.41M | -30.3M | -10.4M | -7.07M | -15.1M |
| EBITDA | - | 284K | -8.74M | -1.10M | 1.88M | -6.29M |
| Net Income | -12.2M | -8.58M | -30.4M | -10.9M | -7.72M | -15.6M |
| EPS | -0.17 | -0.12 | -0.41 | -0.15 | -0.10 | -0.20 |
| Balance Sheet | ||||||
| Total Assets | 102M | 96.1M | 65.8M | 50.3M | 50.8M | 50.7M |
| Total Liabilities | 18.8M | 21.7M | 21.8M | 17.2M | 16.3M | 24.0M |
| Shareholders' Equity | 83.0M | 74.4M | 44.0M | 33.1M | 34.5M | 26.7M |
| Cash & Short-term Investments | 41.2M | 32.6M | 12.9M | 5.77M | 10.2M | 4.82M |
| Cash Flow | ||||||
| Operating Cash Flow | -695K | -622K | -9.46M | 101K | 2.41M | -2.56M |
| Capital Expenditure | 2.55M | 2.13M | 3.55M | 0.00 | 191K | 88.0K |
| Free Cash Flow | -3.24M | -2.75M | -13.0M | 101K | 2.22M | -2.65M |
| Ratios | ||||||
| ROE | -14.8% | -11.5% | -68.9% | -33.0% | -22.4% | -58.3% |
| ROA | -12.0% | -8.9% | -46.1% | -21.7% | -15.2% | -30.7% |
| Net Profit Margin | -43.4% | -23.7% | -101.3% | -31.1% | -19.9% | -50.6% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Glycorex Transplantation AB (publ) dividends
Glycorex Transplantation AB (publ) has not paid dividends in the last 5 fiscal years.
Who owns Glycorex Transplantation AB (publ)
- Insiders 0.00%
- Institutions 0.00%
- Public & others 100.00%
- Shares outstanding 75.6M
- Free float 55.4M
Glycorex Transplantation AB (publ) company profile
- Company name
- Glycorex Transplantation AB (publ)
- Ticker
- O33.F
- ISIN
- SE0000524530
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 20
- Fiscal year end
- December
- Address
- ScheelevAegen 27, Lund, Sweden, 223 63
- Phone
- 46 4 62 86 52 30
- Website
- glycorex.com
About Glycorex Transplantation AB (publ)
Glycorex Transplantation AB (publ), a medical technology company, research, develops, manufactures, markets, and sells products in the field of organ transplantation or related areas. It develops an antigen-specific immunoadsorption to reduce blood group antibodies and autoantibodies in the blood. The company's principal product is Glycosorb-ABO, which enables blood group incompatible kidney transplantation and is also used to enable heart, liver, lung, and stem cell transplantation procedures. It serves in the United Kingdom, Australia, Scandinavia, Spain, Germany, and Austria. Glycorex Transplantation AB (publ) was incorporated in 1995 and is headquartered in Lund, Sweden.
Glycorex Transplantation AB (publ) management
1- Carl-Magnus SchultzChief Executive Officer · born 1970